Mechanisms of human immunodeficiency virus type 1 (HIV-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody

被引:29
|
作者
McDougal, JS [1 ]
Kennedy, MS [1 ]
Orloff, SL [1 ]
Nicholson, JKA [1 ]
Spira, TJ [1 ]
机构
[1] CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,IMMUNOL BRANCH,ATLANTA,GA 30333
关键词
D O I
10.1128/JVI.70.8.5236-5245.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
An assay for the neutralization of human immunodeficiency virus type 1 (HIV-1) is described in which the reduction in infectious titer of HIV-1 after preincubation at 37 degrees C with antibody-positive serum is the measure of neutralization. The assay format and its controls allow several experimental manipulations that, taken together, indicate an effect of antibody on HIV-1 infectivity that occurs before or independently of HIV-1 attachment. The direct inactivation of HIV-1 infectivity by antibody is irreversible and temperature dependent, requires a bivalent antibody directed against accessible envelope determinants, and does not require a heat-labile or Ca2+ or Mg2+-dependent cofactor. The mechanism of inactivation cannot be explained by agglutination of virus, nor is it associated with disruption or dissociation of envelope protein from virions, Rather, the antibody is likely to perturb some metastable property of the envelope that is required for entry, Laboratory-adapted HIV-1 isolates were more sensitive to the inactivating effects of sera than were primary patient isolates, The latter were particularly resistant to inactivation by contemporary autologous sera, a feature not explained by blocking antibodies, Additional studies showed a weak relationship between disease course and serum inactivation of the reference LAI laboratory strain of HIV-1. Heteroduplex analysis and autologous inactivation assays of sequential specimens from individual patients indicate that over time, the viral quasispecies that emerge and dominate are resistant to the inactivating effects of earlier sera.
引用
收藏
页码:5236 / 5245
页数:10
相关论文
共 50 条
  • [41] Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B
    Frost, SDW
    Liu, Y
    Pond, SLK
    Chappey, C
    Wrin, T
    Petropoulos, CJ
    Little, SJ
    Richman, DD
    JOURNAL OF VIROLOGY, 2005, 79 (10) : 6523 - 6527
  • [42] Antibody neutralization and escape by HIV-1
    Wei, XP
    Decker, JM
    Wang, SY
    Hui, HX
    Kappes, JC
    Wu, XY
    Salazar-Gonzalez, JF
    Salazar, MG
    Kilby, JM
    Saag, MS
    Komarova, NL
    Nowak, MA
    Hahn, BH
    Kwong, PD
    Shaw, GM
    NATURE, 2003, 422 (6929) : 307 - 312
  • [43] Frequency of human immunodeficiency virus (HIV) infection among contemporary anti-HIV-1 and anti-HIV-1/2 supplemental test-indeterminate blood donors
    Busch, MP
    Kleinman, SH
    Williams, AE
    Smith, JW
    Ownby, HE
    Laycock, ME
    Lee, LLL
    Pau, CP
    Schreiber, GB
    TRANSFUSION, 1996, 36 (01) : 37 - 44
  • [44] Antibody neutralization and escape by HIV-1
    Xiping Wei
    Julie M. Decker
    Shuyi Wang
    Huxiong Hui
    John C. Kappes
    Xiaoyun Wu
    Jesus F. Salazar-Gonzalez
    Maria G. Salazar
    J. Michael Kilby
    Michael S. Saag
    Natalia L. Komarova
    Martin A. Nowak
    Beatrice H. Hahn
    Peter D. Kwong
    George M. Shaw
    Nature, 2003, 422 : 307 - 312
  • [45] Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission
    Lehman, Dara A.
    Farquhar, Carey
    REVIEWS IN MEDICAL VIROLOGY, 2007, 17 (06) : 381 - 403
  • [46] Inactivation and purification of human immunodeficiency virus-1 as antigen for the treatment of HIV-1 infection
    Prior, CP
    Gore, R
    Harter, J
    Berbaum, M
    Duffy, C
    Ferre, F
    Hancock, R
    Lowry, P
    Musil, R
    Stiglitz, M
    Carlo, DJ
    Richieri, SP
    Maigetter, RZ
    BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS, 1996, 9 (09): : 22 - &
  • [47] ASSOCIATION BETWEEN ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ANTIBODY-TITERS AT BIRTH AND VERTICAL TRANSMISSION OF HIV-1
    JENKINS, M
    LANDERS, D
    WILLIAMSHERMAN, D
    WARA, D
    VISCARELLO, RR
    HAMMILL, HA
    KLINE, MW
    SHEARER, WT
    CHARLEBOIS, ED
    KOHL, S
    JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (02): : 308 - 312
  • [48] Detection of human immunodeficiency virus type 1 (HIV-1) RNA in pools of sera negative for antibodies to HIV-1 and HIV-2
    Morandi, PA
    Schockmel, GA
    Yerly, S
    Burgisser, P
    Erb, P
    Matter, L
    Sitavanc, R
    Perrin, L
    JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (06) : 1534 - 1538
  • [49] Mechanisms contributing to the neutralization of HIV-1
    ZollaPazner, S
    IMMUNOLOGY LETTERS, 1996, 51 (1-2) : 89 - 93
  • [50] The effect of human immunodeficiency virus type 1 (HIV-1) gp41 variability on antibody detection
    Nie, Jianhui
    Song, Aijing
    Xu, Sihong
    Li, Xiuhua
    Wang, Youchun
    ARCHIVES OF VIROLOGY, 2010, 155 (11) : 1813 - 1822